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Extracts of both rat hypothalamus and pancreas were analyzed for their corticotropin releasing factor 
(CRF)-like immunoreactivity by radioimmunoassay (RIA). In the case of the hypothalamus, besides the 
rat CRF, further identified by high-pressure liquid chromatography (HPLC), two peptide components, a 
20-kDa and a IO-kDa species were detected. The 20-kDa component was stable under acidic pH conditions 
and was further purified by reverse-phase HPLC. When exposed to proteolytic activities coeluting with 
‘high-molecular-mass CRF’ at pH 6, processing was observed and the CRF generated was identified both 
by RIA, molecular sieve filtration and HPLC under different experimental conditions. It is concluded that 
this 20-kDa CRF may represent he CRF precursor and that hypothalamic extracts may contain processing 
enzymes involved in its selective post-translational cleavage. In the pancreatic extract two immunoreactive 
forms of CRF were detected, the smaller coeluting with the rat CRF and the other corresponding to the 
intermediate IO-kDa component detected in the hypothalamus. Pancreatic rat CRF, analyzed using RIA 
both by molecular sieve filtration and HPLC, was indistinguishable from the hypothalamic rat CRF. 
Corticotropin precursor Proteolytic enzyme HPLC Corticotropin RIA 
1. INTRODUCTION 
Direct evidence for an hypothalamic cor- 
ticotropin (ACTH) releasing factor (CRF) that 
stimulates ACTH secretion from the pituitary 
gland was first reported in 1955 fl,2]. More than 
25 years later, isolation and sequencing of a 
41-amino-acid hypothalamic peptide from ovine 
(o-CRF) [3,4] and rat (r-CRF) [5], with cor- 
ticotropin releasing activity were performed. 
The available data suggest that the h~oth~amic 
CRF enhances ynthesis and secretion not only of 
ACTH but also of related peptides such as B- 
endorphin, B-lipotropin and a-melanocyte- 
* To whom reprint requests should be sent 
stimulating hormone [6,7]. Moreover, it has been 
shown that o-CRF also stimulates somatostatin 
secretion from cultured brain cells [8]. Recently the 
primary structures of the biosynthetic precursor of 
both ovine CRF [9] and human CRF [lo] were 
predicted by determining the nucleotide sequence 
of the cloned DNA complementary to the mRNA 
encoding the precursor. Indeed, a number of hor- 
monal peptides have been detected both in the cen- 
tral nervous system and in the gastrointestinal tract 
[ 11,121. This differential organ distribution may 
reflect the different biological role of these com- 
pounds 1131. Recently immunohistochemical 
studies revealed pancreatic systems that stain with 
antiserum to CRF [14]. Whether this material 
represents chemically authentic CRF was unclear. 
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All these data are consistent with a multiple, ex- 
tracellular, regulatory role for CRF. 
However to date: (i) in the hypothalamus no 
direct experimental evidence for the presence of 
CRF precursor molecules and for their processing 
has been reported; (ii) no analysis and biochemical 
characterization of the pancreatic immunoreactive 
CRF component have been performed. 
Here we have characterized, in the rat 
hypothalamus, a high-molecular-mass peptide im- 
munologically related to CRF, that can be con- 
verted into CRF by a proteolytic activity present in 
the hypothalamic extract. We have also shown that 
the pancreatic CRF-like peptide, characterized by 
several methods including HPLC, is identical to 
hypothalamic CRF. 
2. MATERIALS AND METHODS 
2.1. Extracts and fractionation 
Rat hypothalami (5 fragments) or rat pancreas 
(2 fragments) were removed immediately after 
death by rapid decapitation and homogenized in a 
Potter Elvejhem (clearance 25 pm) in 2 ml of 
0.2 N HCl, 8 M urea. After centrifugation for 1 h 
at 100000 x g (Beckman LS 50, SW 50 rotor) the 
supernatant was submitted to gel filtration over a 
Sephadex G-75 column (1.6 x 90 cm) equilibrated 
and eluted with 0.1 N HCOOH at 4°C. Further 
fractionation of the different molecular mass 
species was performed over a Sephadex G-75 col- 
umn (0.9 x 50 cm) under the same conditions as 
above. 
2.2. High-pressure liquid chromatography 
(HPLC) 
The HPLC system consisted of a Beckman ap- 
paratus (pumps A 110, directed by a 421 con- 
troller). Reverse-phase HPLC was performed us- 
ing a PBondapack CN column (Waters) under the 
conditions described in the figure legends. 
2.3. CRF radioimmunoassay 
Radioimmunological detection of CRF was per- 
formed using an antiserum raised against o-CRF 
(231 06 07) at a final dilution of l/30000 in a 
medium containing potassium phosphate buffer 
(pH 7.4), 0.25 M NaCI, 2.5 mg/ml BSA and 0.1% 
Triton X-100. ‘251-labelled Tyr o-CRF (ovine), ob- 
tained by labeling of Tyr-0-CRF (Peninsula 
Laboratories, San Carlos, CA) with the lac- 
toperoxidase method, was used as marker. The an- 
tigens (either the standard peptide or a biological 
sample) were first preincubated 24 h with the anti- 
CRF immune serum, then the tracer was added 
and the mixture left for 18 h. The free iodinated 
peptide was separated from the bound peptide by 
the double-antibody method using anti-rabbit rg 
globulins and 1 ml of 6% polyethylene glycol. 
Under these conditions the detection limit was 
2 pg/test and a 50% displacement of the tracer was 
obtained with 7 pg/test (1.4 fmol) of o-CRF. The 
cross-reaction with biosynthetic r-CRF was only 
50%. In the CRF radioimmunoassay, controls 
were systematically performed to establish that the 
measured immunoreactivity was not due to either 
degradation of the labeled tracer or to sticking to 
a protein component. 
3. RESULTS 
Analysis of rat hypothalamic extracts by 
molecular sieve filtration over a Sephadex G-75 
column (fig.1) resolved two major immunoreactive 
peaks and one minor intermediate peak. The lower 
M, immunoreactive species was identified as r-CRF 
as it coeluted with synthetic o-CRF or r-CRF 
filtered under the same conditions and tested by 
RIA. The apparent molecular mass of the large im- 
munoreactive form of r-CRF was 20 kDa f 10% 
(calculated by comparison with the elution volume 
of globular proteins used for calibration). Control 
experiments were conducted to verify this large ap- 
parent molecular mass. The elution profile and the 
apparent molecular mass of the immunoreactive 
20-kDa material were unmodified when reanalyzed 
by the same molecular sieve filtration after 2 h ex- 
posure to 8 M urea (fig.1, inset). These results in- 
dicate the presence, in rat hypothalamus extracts, 
of a higher M, component immunologically related 
to r-CRF, and which is not an aggregate of lower 
size antigens. Under the same conditions, analysis 
of the rat pancreatic extract showed a relatively 
similar pattern (fig. 1) except that the 20-kDa com- 
ponent was not detectable. This may be due to the 
high content of protease activity present in the 
pancreas as compared to the hypothalamus. 
However, the major immunoreactive peak 
detected in the pancreatic extract filtration has the 
same molecular mass as the hypothalamic CRF. 
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Fig. 1. Molecular sieve filtration of CRF immunoreactive 
forms extracted from rat hypothalamus and rat 
pancreas. An acid/urea extract of hypothalami or 
pancreas was submitted to gel filtration over a Sephadex 
G-75 column (1.6 x 90 cm) equilibrated and eluted with 
0.1 M HCOOH (10 ml/h) at 4°C. An aliquot of each 
fraction (1 ml) was tested for CRF immunoreactivity: 
hypothalamic extracts (+---e), pancreatic extracts 
(A---A). Results are expressed as pg CRF/test. The 
arrow indicates the elution position of synthetic rat CRF 
filtered under the same conditions. V,, exclusion 
volume. (Inset) Analysis of the hypothalamic 20-kDa 
species recovered from the Sephadex G-75 gel filtration 
step. The high-molecular-mass immunoreactive material 
(fractions 40-50 of the gel filtration) was lyophilized, 
resuspended for 2 h in 1 ml acid/urea buffer and 
reanalyzed on a Sephadex G-75 column (0.9 x 50 cm at 
5 ml/h). CRF immunoreactivity was tested on each 
fraction (1 ml), and the results expressed as above. The 
arrow indicates the elution position of the synthetic rat 
CRF. 
Precursor-product relationships between the 
20-kDa form and hypothal~ic r-CRF were assess- 
ed by in vitro conversion experiments and the pro- 
ducts were analyzed using reverse-phase HPLC. 
The hypothalamic r-CRF material isolated by 
molecular sieve filtration (fig.1) was applied to a 
PBondapack CN column and eluted with a linear 
gradient of acetonitrile (0.44~~/min) in aqueous 
0.1% trifluoroacetic acid (TFA). After elution the 
r-CRF immunoreactivity was recovered as a major 
peak (retention time: 56 min) corresponding to 
80% of the total immunoreactive material 
recovered (fig.ZA). This main species coelutes with 
synthetic r-CRF run under the same gradient con- 
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Fig.2. Processing of the purified high-molecular-mass 
species by hypothalamic enzyme activity. (A) Fractions 
corresponding to the r-CRF recovered from the 
Sephadex G-75 column of fig.1 were pooled, 
lyophilized, then redissolved in 0.5 ml of 1% TFA and 
applied to a PBondapack CN column (4 x 250 mm). 
After injection, the product was eluted with a linear 
gradient of acetonitrile (0.44%/min) at a flow rate of 
1 ml/min over 90 min. Each fraction (1 ml) was tested 
for CRF immunoreactivity. (B) chromatography of the 
high-molecuiar-mass pecies (20 kDa) recovered from 
the Sephadex G-75 column of fig. 1. Same conditions as 
in A. (C) An aliquot of the 20-kDa material recovered 
from the experiment of fig.1 was incubated for 1 h at 
37°C in ammonium acetate buffer (pH 6), in the 
presence of 100 kallikrein inhibitor units (KIU)/ml of 
aprotin~n. After incubation, the medium was acidified 
with 1% TFA and submitted to a filtration on 
pBondapack CN column under the same conditions as in 
A. Results are expressed as pg CRF/test. The arrows 
indicate the elution position of synthetic r-CRF filtered 
in the same conditions, and of the 20-kDa polypeptide. 
ditions. The two minor peaks (retention time 49 
and 52 min, respectively) probably correspond to 
hypothalamic r-CRF molecules slightly modified 
during the extraction procedure, since they were 
recognized by the anti-CRF antibodies and have a 
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molecular mass similar to that of synthetic r-CRF 
by molecular sieve filtration (not shown). 
Under the same gradient conditions the 20 kDa 
CRF-like product, first purified by gel filtration, 
was eluted with a retention time of 63 min (fig.2B). 
This higher M, material, recovered from the ex- 
periment of fig. 1, was submitted to a processing 
experiment. This material was first lyophilized and 
resuspended in 0.1 M phosphate buffer (pH 6) in 
the presence of 100 kallikrein inhibitor units/ml of 
aprotinin to avoid non-specific degradation by 
serine proteases present in the extract. The mixture 
was then incubated for 1 h at 37°C. Under these 
conditions specific proteolytic activity coeluting 
with the 20 kDa polypeptide was able to process 
this material. Analysis of the products thus 
generated by means of reverse-phase HPLC filtra- 
tion showed (fig.2C) two main distinct im- 
munoreactive forms. A noticeable fraction of 
uncleaved 20-kDa pro-form together with the im- 
munoreactive species eluting with the same reten- 
tion time as the hypothalamic r-CRF were ob- 
served. In addition, we also found the two minor 
components described above (fig.2A). Analysed by 
molecular mass filtration, the 20-kDa species 
generates an immunoreactive CRF-like peptide 
which coelutes with synthetic or hypothalamic r- 
CRF when filtered over Sephadex G-75 (not 
shown). Further identification of both the im- 
munoreactive hypothalamic peptide generated by 
the processing experiment and the pancreatic im- 
munoreactive CRF-like component was achieved 
by reverse-phase HPLC analysis under isocratic 
conditions. This allowed separation of the o-CRF 
(retention time 25 min) from the r-CRF (retention 
time 38 min), which exhibits 7 amino acid substitu- 
tions in comparison with the o-CRF sequence. 
Fig.3 shows first that the immunoreactive peptide 
generated by the processing experiment repre- 
sented in fig.2C has the same retention time as the 
synthetic r-CRF, and second that when the pan- 
creatic peptide isolated by molecular sieve filtra- 
tion (fig.1) is filtered under the conditions de- 
scribed above, it coelutes with the synthetic r-CRF. 
These observations indicate (i) that the 20-kDa 
component may represent he biosynthetic precur- 
sor of the CRF, and (ii) that pancreatic tissues con- 
tain a peptide exhibiting an immunological and 
biochemical behaviour similar to the rat CRF. 
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Fig.3. HPLC of the generated hypothalamic r-CRF-like 
peptide and of pancreatic CRF. The r-CRF 
immunoreactivity recovered from filtration in fig.2C 
was lyophilized, solubilized in 0.5 ml of 1% TFA and 
injected on a pBondapack CN column. Elution was 
performed under isocratic conditions with 35% 
acetonitrile in aqueous 0.1% TFA (v/v), at a flow rate 
of 1 ml/min over 50 min (hatched bars). The pancreatic 
r-CRF material recovered from Sephadex filtration 
(fig.1) was filtered through the pBondapack column 
under the same conditions as above (M); each frac- 
tion (1 ml) was tested for CRF immunoreactivity. The 
arrows indicate the elution position of both synthetic 
o-CRF and synthetic r-CRF, filtered under the same 
conditions. 
4. DISCUSSION 
The present data provide immunological and 
biochemical evidence for the presence of a 20-kDa 
(+ 2 kDa) immunoreactive form of CRF in rat 
hypothalamus extracts. This value is close to those 
of the ovine or human pre-pro-CRF molecules, 
calculated from their primary structure (minus the 
signal peptide sequence) as deduced from the cor- 
responding cDNA or gene sequences [9,10]. The 
demonstration that this 20-kDa hypothalamic CRF 
can generate the r-CRF peptide by proteolytic 
cleavage suggests that it can be considered as a 
biosynthetic precursor of this hormone (fig.3). In 
the pancreas extract, the high content of protease 
activity present in this organ might explain the in- 
ability to detect this 20-kDa species. The minor 
intermediate-size immunoreactive components 
(10 kDa) also observed by molecular sieve filtra- 
tion of both hypothalamic and pancreatic extracts 
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(fig.1, fractions 50-55) may represent in- 
termediates in the post-translational events leading 
from the larger precursor to the ‘final’ secretory 
product. Analyzed by reverse-phase HPLC, this 
minor product eluted as a single immunoreactive 
peak with a retention time between those of the 
20-kDa species and r-CRF (not shown). 
Apart from its role as hypothalamic releasing 
factor, CRF appears to be a typical ‘gut-brain’ 
peptide, localized both in neurones throughout the 
brain and in the pancreas. The functional 
significance of this finding is as yet unknown. 
However, it has been shown that CRF (as well as 
the related peptides sauvagine and urotensin I) 
possesses vasomotor activity [ 15,161. Thus, pan- 
creatic CRF may play a hormonal role in the local 
regulation of blood flow through the endocrine or 
exocrine pancreas. Whether this CRF is synthe- 
sized by the pancreatic tissue or by exogenous 
neural cells innervating the pancreas remains to be 
established. 
Examination of the sequences of both human 
CRF and of the corresponding precursor [lo] 
shows the presence of basic amino acid doublets in 
the C-terminal portion of the CRF molecule and in 
the pro-sequence preceding the CRF peptide in the 
precursor. Assuming that these doublets or double 
pairs of basic amino acids constitute the recogni- 
tion sites for selective endopeptidases [171, a 
number of fragments can be expected from post- 
translational processing of the pro-CRF molecule. 
Furthermore, an internal peptide can also be ex- 
pected to be released by cleavage at position 35 of 
the CRF41 [5]. Therefore, the pleiotropic actions 
exhibited by this peptide in the central nervous 
system or in the pancres [14,18,19] might reflect a 
differential processing of the precursor and 
hormone. 
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